<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="335780">
  <stage>Registered</stage>
  <submitdate>3/08/2010</submitdate>
  <approvaldate>16/08/2010</approvaldate>
  <actrnumber>ACTRN12610000667011</actrnumber>
  <trial_identification>
    <studytitle>Evaluation of antioxidant therapy in presbycusis: results of a prospective, randomized, double-blind and controlled clinical trial.</studytitle>
    <scientifictitle>"Evaluation of antioxidant therapy on hearing improvement in presbycusis patients 60 and older: results of a prospective, randomized, double-blind and controlled clinical trial"</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>presbycusis</healthcondition>
    <conditioncode>
      <conditioncode1>Alternative and complementary medicine</conditioncode1>
      <conditioncode2>Other alternative and complementary medicine</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Ear</conditioncode1>
      <conditioncode2>Other ear disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>There are four treatment groups. Group 1: ginkgo biloba, Group 2: alpha lipoic acid with vitamin C, Group 3: papaverine hydrochloride with vitamin E, and Group 4 (Comparator): starch pill. Dry extract of ginkgo biloba 120 mg once a day, oral tablet taken daily for a total of 6 months, alpha lipoic acid 60 mg in combination with vitamin C 600 mg once a day, oral tablet taken daily for a total of 6 months, and vitamin E 400 mg combined with papaverine hydrochloride 100 mg once a day, oral tablet taken daily for a total of 6 months.</interventions>
    <comparator>starch pill 100 mg once a day, oral tablet taken daily for a total of 6 months</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Primary Outcome: hearing improvement in an audiometric test</outcome>
      <timepoint>Timepoint: at 6 months after intervention commencement</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Efects on tinnitus</outcome>
      <timepoint>nil</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Adults with diagnosis of presbycusis by hearing tests and clinical evaluation.</inclusivecriteria>
    <inclusiveminage>60</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Will be excluded individuals with other causes for hearing loss, known allergy to any substances in question or with medical contraindications to using them. Patients taking anticoagulants or with coagulation disorders and diabetics will also be excluded from the sample.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>120 volunteers numbered containers will be randomly assigned to four different groups:30 individuals will take dry extract of Ginkgo biloba, 30 a-lipoic acid in combination with vitamin C, 30 papaverine hydrochloride in combination with vitamin E and 30 placebo.</concealment>
    <sequence>Volunteers will be randomised by using a randomisation table created by computer software.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>23/08/2010</anticipatedstartdate>
    <actualstartdate>23/08/2010</actualstartdate>
    <anticipatedenddate />
    <actualenddate>13/12/2010</actualenddate>
    <samplesize>120</samplesize>
    <actualsamplesize>120</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Sao Paulo</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other Collaborative groups</primarysponsortype>
    <primarysponsorname>CDA</primarysponsorname>
    <primarysponsoraddress>Borges Lagoa streeet, 783  2nd.floor - room 21 cep 04023-062  Vila Clementino - Sao Paulo  Sao Paulo - Brazil</primarysponsoraddress>
    <primarysponsorcountry>Brazil</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Other Collaborative groups</fundingtype>
      <fundingname>CDA - Centro do Deficiente Auditivo</fundingname>
      <fundingaddress>Borges Lagoa street, 783  2nd.floor - room 21 cep 04023-062 Vila Clementino - Sao Paulo  Sao Paulo - Brazil</fundingaddress>
      <fundingcountry>Brazil</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>nil</sponsorname>
      <sponsoraddress>nil</sponsoraddress>
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The study aimed to evaluate the efficacy of treatment with anti-oxidants in presbycusis, or deafness in the elderly. For this, the volunteers will be divided into four groups and each group will receive one of the following medications: ginkgo biloba, alpha lipoic acid + vitamin C, vitamin E + papaverine and placebo. After six months the hearing will be tested and compared with an initial test to check for hearing improvement with any of these therapies.</summary>
    <trialwebsite />
    <publication>Evaluation of antioxidant treatment in presbyacusis: prospective, placebo-controlled, double-blind, randomised trial.
Polanski JF, Cruz OL.
J Laryngol Otol. 2013 Feb;127(2):134-41. doi: 10.1017/S0022215112003118.</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Ethics Committee of the Federal University of Sao Paulo / Hospital Sao Paulo</ethicname>
      <ethicaddress>Botucatu street, 572-1 st. floor - room 14  cep 04023-062 - Sao Paulo / Brazil</ethicaddress>
      <ethicapprovaldate>2/07/2010</ethicapprovaldate>
      <hrec>CEP 0723/10</hrec>
      <ethicsubmitdate />
      <ethiccountry>Brazil</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Jose Fernando Polanski</name>
      <address>Borges Lagoa street, 783  2nd.floor - room 21 cep 04023-062 Vila Clementino - Sao Paulo  Sao Paulo</address>
      <phone>+55 11 99749470</phone>
      <fax />
      <email>jfpolanski@gmail.com</email>
      <country>Brazil</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Jose Fernando Polanski</name>
      <address>Borges Lagoa street, 783  2nd.floor - room 21 cep 04023-062 Vila  Clementino - Sao Paulo  Sao Paulo</address>
      <phone>+55 41 99749470</phone>
      <fax>nil</fax>
      <email>jfpolanski@gmail.com</email>
      <country>Brazil</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Jose Fernando Polanski</name>
      <address>Rua Borges Lagoa, 783
Vila Clementino
ZIp code 04038-031
Sao Paulo-SP
Brasil</address>
      <phone>55 11 5576 4848 add 2427</phone>
      <fax />
      <email>jfpolanski@gmail.com</email>
      <country>Brazil</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>